Updated:
Oncotelic Therapeutics
Vuong Trieu's Oncotelic Therapeutics operates a dual-track biotech and AI-CRO model built around TGF-β oncology assets and repurposed antiviral drugs.
Oncotelic Therapeutics
Oncotelic Therapeutics was formed from the reverse merger of Mateon Therapeutics with POINT International, shifting its focus toward immunotherapy and repurposed drug assets. The company's foundational claim centers on OT-101, a TGF-β antisense compound, which a multi-center clinical trial tested against pancreatic cancer and glioblastoma. Vuong Trieu, the firm's longtime steward, previously guided the clinical development of blockbuster chemotherapies like Abraxane, creating a leadership team with deep expertise in navigating the FDA's accelerated-approval pathways. The firm structures its drug development through joint ventures and wholly owned subsidiaries rather than pure internal programs. Its portfolio spans OT-101 for oncology, a repurposed antiparasitic called Mefloquine explored through the joint venture OncoVaxx, and an AI platform via its subsidiary AL+ that analyzes candidate molecules. The JV structure is deliberately pragmatic — it isolates specific candidate risk in separate vehicles to potentially attract non-dilutive project financing. The repurposed therapeutic candidates target large, orphan, and pandemic-scale viral diseases, mapping to unmet needs in pancreatic cancer, Parkinson's disease, and post-COVID cognitive impairment. Oncotelic maintains a lean public-company structure with a market capitalization typically between $20 million and $50 million, though precise historical deployment into clinical trials is not consolidated into a single fund vehicle. A May 2024 SEC filing confirmed Vuong Trieu continues to serve as both Chairman and CEO, consolidating decision-making authority over the clinical pipeline and the strategic direction of the AI subsidiary. The company operates from Agoura Hills, California. The structural differentiator is the dual-track mechanism: Oncotelic is neither a pure-play biotech nor a standard incubator. It holds proprietary drug assets on its balance sheet but simultaneously monetizes scientific expertise through its AI-CRO subsidiary, which offers discovery services to third parties. This hybrid revenue model — combining clinical milestone economics with fee-for-service AI analytics — provides a degree of operational funding that most development-stage biotechs lack.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Agoura Hills
Corporate office
Agoura Hills, CA, United States
Principals
Vuong Trieu
Chairman and CEO
Sector focus
Frequently asked questions
What is Oncotelic's lead therapeutic candidate?
OT-101, a TGF-β antisense oligonucleotide, is the lead asset. A Phase 3 clinical trial evaluated OT-101 in combination with chemotherapy for pancreatic cancer, and additional studies explored its activity against glioblastoma. The compound targets the TGF-β pathway, which is implicated in tumor growth, metastasis, and immune evasion across multiple cancer types.
How does the AI subsidiary relate to the core biotech operations?
The subsidiary uses an artificial intelligence platform to identify and optimize therapeutic candidates, effectively functioning as a contract research AI service. This creates a secondary revenue stream: the platform can be leveraged for Oncotelic's internal pipeline while also generating fees from third-party drug discovery programs, blurring the boundary between a therapeutic developer and a service provider.
Why does the firm structure drug programs through joint ventures rather than holding all assets directly?
The joint venture model, exemplified by OncoVaxx's work on Mefloquine, isolates clinical and financial risk into separate entities. For a micro-cap company with constrained resources, this architecture allows the firm to advance specific programs using project-specific financing or partner capital without exposing the parent entity's entire balance sheet to a single binary clinical outcome.
Is Oncotelic a biotech operating company or an investment vehicle?
It functions primarily as a drug development operating company with its own clinical pipeline, not a passive investment fund. However, the wholly owned AI subsidiary and the separate JV structures introduce elements of a venture-studio model where discovery services generate operational income. There is no evidence the firm allocates third-party external capital as a traditional fund manager.
What does the repurposed drug program target beyond oncology?
Through joint ventures, the firm is investigating repurposed agents like Mefloquine for broad-spectrum antiviral activity. Development targets include diseases with pandemic potential and post-viral syndromes, specifically studying applications for post-COVID cognitive dysfunction and Parkinson's disease. This pivot toward repurposed antiparasitics dramatically expands the addressable patient population beyond rare tumors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: